New medicine for the prevention of migraine
Monoclonal antibody Emgality recommended for marketing authorisation
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Emgality (galcanezumab), a monoclonal antibody for the prevention of migraine. Emgality belongs to a new class of medicines that work by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule that is involved in migraine attacks.
It is estimated that approximately 15% of the population in the European Union suffers from migraine. Patients experience recurrent episodes of intense, throbbing headache, most often only on one side of the head. Sometimes, the pain is preceded by visual or sensory disturbances known as an ‘aura’. Many people also experience nausea, vomiting and increased sensitivity to light or sound. Migraine can substantially impair a patient’s ability to function physically, at work or school, and socially.
The exact cause of migraine is unknown, but it is believed to be a neurovascular disorder with disease mechanisms both within the brain and the blood vessels of the head. It is most frequent in women and has a strong genetic component.
Emgality will be available as a solution for injection intended only for patients who have at least 4 migraine days per month. The benefits and safety of Emgality were studied in three pivotal trials involving 1,780 patients with episodic migraine and 1,117 with chronic migraine. After six months of treatment, patients with episodic migraine showed a reduction of 1.9 monthly migraine days on average compared to placebo. For patients with chronic migraine the reduction was 2 days. The most common side effects are pain and reactions at the injection site, vertigo and constipation.
Emgality is the second monoclonal antibody therapy for the prevention of migraine to be recommended for authorisation, following the positive opinion for Aimovig (erenumab) in May 2018. There is no cure for migraine and these two medicines widen the therapeutic options for this disease. There are other available treatments to tackle the symptoms and reduce the frequency of migraine days. However, existing preventative treatments do not always work well and may have unpleasant side effects.
The opinion adopted by the CHMP is an intermediary step on Emgality’s path to patient access. The CHMP opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation. Once a marketing authorisation has been granted, decisions about price and reimbursement will take place at the level of each Member State, taking into account the potential role/use of this medicine in the context of the national health system of that country.
- The applicant for Emgality is Eli Lilly Nederland B.V.
|New medicine for the prevention of migraine||(English only)||21/09/2018|
Latest News from
EU negotiators agree to facilitate access to online TV and radio content across borders14/12/2018 11:37:00
The negotiators of the EC, the European Parliament and the Council, have reached a political agreement on the proposed copyright legislation on TV and radio programmes.
Agreement on EC proposal to boost the use of organic and waste-based fertilisers13/12/2018 16:25:00
The EU institutions have found an agreement on new EU rules on fertilisers proposed by the EC in 2016 as a key deliverable of the Circular Economy Package.
European Citizens' Initiative: Political agreement reached on the EC’s proposal13/12/2018 14:37:00
The European Parliament and the Council reached a political agreement on the EC’s proposal to revise the European Citizens' Initiative, an instrument which allows 1m European citizens to ask the Commission to submit a legislative proposal.
EU-Japan trade agreement on track to enter into force in February 201913/12/2018 13:10:00
The trade agreement negotiated by the EC is the first ever to include an explicit reference to the Paris climate agreement. It will create an open trading zone covering 635m people and almost one third of the world's total GDP.
Multiannual management plan for Western Waters: provisional agreement confirmed by the Council13/12/2018 12:25:00
The management of fisheries in Western waters will soon benefit from a longer term and more consistent set of rules established jointly by all EU institutions.
Import of fishery products: Council agrees on autonomous EU tariff quotas for the period 2019-202013/12/2018 11:10:00
In 2019 and 2020 the EU fish processing industry will continue to import raw material for further processing from non-EU countries at reduced rates or duty free.
Extended internal market and EU relations with non-EU Western European countries13/12/2018 09:25:00
Council conclusions on a homogeneous extended internal market and EU relations with non-EU Western European countries
Agreement on new rules to fight non cash payment fraud12/12/2018 16:33:00
The EU is stepping up the fight against fraud involving non-cash means of payment (credit cards, online shopping, etc.) by upgrading and modernising the existing rules.
EC approves acquisition of Gemalto by Thales, subject to conditions12/12/2018 15:25:00
The EC has approved under the EU Merger Regulation the proposed acquisition of Gemalto by Thales. The approval is conditional on the divestment of Thales' general purpose hardware security modules business.
EC welcomes the adoption of stronger rules to stop cyber-criminals12/12/2018 14:47:00
The European Parliament and the Council reached political agreement on the EC’s proposal to strengthen rules to combat fraud and counterfeiting of non-cash means of payment – such as bank cards, cheques, mobile payments and virtual currencies.